A PBM Fee Is Not a Performance Measure
When pharmacy spending is under pressure, a simple fee can feel like a simple answer. A plan sponsor sees a per-member charge, a rebate guarantee, or a promised savings percentage and wants a clear verdict: good deal or bad deal.
But a fee describes a price. It does not, by itself, describe the work performed, the other money moving through the arrangement, or whether employees can get the prescriptions they need without unnecessary friction.
The source idea: compensation should be connected to cost performance
On October 16, CMS proposed new reporting and compensation requirements for PBMs serving Medicare Advantage and Part D plans. The proposal would require PBMs to report compensation and cost performance annually, and it would require certain payments to reflect fair-market-value services rather than drug costs. This is a proposed rule for Medicare markets; it does not directly set requirements for a self-funded employer plan.
Its practical idea is still useful for employer leadership. Pharmacy purchasing gets easier to govern when compensation can be traced to an identified service and reviewed alongside the result that service produced.
Separate the price of administration from the price of the drugs
A self-funded employer does not need to assume that every PBM fee is a problem. Administration, clinical support, specialty-pharmacy coordination, data, and member assistance all take work. The more useful question is whether the plan can identify the service, the payment, and the measure that tells the committee whether that service is helping.
Start with a map. List payments from the plan, payments from manufacturers, payments to pharmacies, and amounts connected to affiliates or specialty channels. Then pair each material service fee with a small number of operating measures: turnaround time, medication access, member disruption, formulary exceptions, specialty outcomes, or a defined clinical goal. A rebate total and a trend percentage may belong in the review, but they should not stand in for the whole map.
Make the report decision-ready
A CFO should be able to ask, “What did we buy, what did we pay, and what changed?” A strong answer draws from the contract, the implementation terms, and the recurring report. If those three sources use different definitions for a fee, a savings claim, or a guarantee, the committee has a question to resolve before it treats the dashboard as a decision.
The same discipline matters during an RFP or a PBM change. A low quoted fee may be meaningful. It may also omit a service the current arrangement includes, depend on an assumed formulary change, or leave an affiliate payment unexplained. The right comparison puts the service scope and the financial definitions beside the promised result.
Turn questions into ownership
Paul H. Flowers Jr. at Superior Insurance Advisors and Paul.Health helps employers turn pharmacy-benefit reports into a review that leadership can use. The aim is not to label a vendor’s revenue as improper or to promise a particular result. It is to make the plan’s questions specific enough that the people responsible for the benefit can get clear answers and act on them.
Source: Centers for Medicare & Medicaid Services, “CMS Proposes Reforms to Strengthen Transparency and Affordability in Medicare Advantage and Part D”, October 16, 2026. The proposed rule discussed applies to Medicare Advantage and Part D, not directly to self-funded employer plans. This is original educational commentary, not legal, tax, investment, or fiduciary advice. Plan documents, contracts, and applicable law govern.
Five questions for the next PBM meeting
- Can we name each material pharmacy-benefit service and its related payment?
- Which payments are paid by the plan, passed through, retained, or tied to an affiliate?
- What contract definition supports each savings or performance number in the report?
- Which member-access and clinical measures sit beside the financial results?
- Who owns each unanswered question before the next renewal or amendment?
Before accepting the next pharmacy report, can your leadership team explain the fee, the service, and the result in the same meeting?